Silusyne e
Silusyne e
Silusyne e
anti-cellulite
slimming
Reduces adipogenesis
by decreasing PGC-1
Description
Science
Appearance
Suspension containing 0.05% active ingredient.
INCI
Water (Aqua), Soybean (Glycine Soja) Oil,
Propanediol, Sorbitan Sesquioleate, Isohexadecane,
Hydroxypropyl Starch Phosphate, Sclerotium Gum,
Sodium Hyaluronate, Lauryldimonium Hydroxypropyl
Hydrolyzed Soy Protein, Acetyl Hexapeptide-39.
Paraben free.
Properties
silusyne reduces adipogenesis by decreasing
PGC-1 expression. This new ingredient helps
to improve the appearance of visible cellulite as
dermo-hypodermal junction irregularities are
smoothed.
Dosage 2%
Applications
silusyne is a perfect ingredient for anti-cellulite
and slimming treatments and as a complement in
any type of body care formulations.
Solubility
Dispersible in water.
www.lipotec.com
silusyne
In vitro efficacy
1. EFFECT ON PGC-1 EXPRESSION
36.5%
di No
ffe nre tre
nt at
ia ed
te n
d o
ce nlls
di
ffe
re No
nt n
ia -tr
te ea
d te
A
ce d
ce
lls
ty
lH
ex
ap
e
(2 ptid
5 e
A
g/ -39
ce
m
ty
l)
lH
ex
ap
(1 ept
00 id
g e/m 39
l)
Relative quantity of
PGC-1 mRNA (%)
16.7%
67.2%
di No
ffe nre tre
nt at
ia ed
te n
d o
ce nlls
di
ffe
N
re o
nt n
ia -tr
te ea
d te
Ca
ce d
ffe
lls
in
e
(2
00
g
A
/m
ce
ty
l)
lH
ex
ap
e
(2 ptid
A
5 e
ce
g/ -39
ty
m
lH
l)
ex
ap
(1 ept
00 id
g e/m 39
l)
29.9%
Cells treated
with silusyne
shows lower lipid
accumulation
than cells treated
with caffeine
In vivo efficacy
EVALUATION OF DERMO-HYPODERMAL JUNCTION
Dermo-hypodermal junction
line decrease (mm)
In order to study the efficacy of silusyne as an anti-cellulite and slimming ingredient, a decrease
in length of the dermo-hypodermal junction was measured. This represents an improvement of
the cutaneous and subcutaneous tissue uniformity.
20 female volunteers (aged 25 to 45) applied a cream containing 2% silusyne on one thigh and
a placebo cream on the other twice a day for 3 weeks.
An ultrasound ecograph in B-scan mode (Ultrasound Scanner Dermascan C) was used to
measure the length of the dermo-hypodermal junction line.
21%
0 weeks
3 weeks
While the claims and supporting data provided in this publication are believed to be reliable and they are presented free and for guidance only, there are no warranties of any kind. All express and
implied warranties are disclaimed. The recipient is solely responsible for ensuring that products marketed to consumers comply with all relevant laws and regulation. LIPOTEC is the exclusive holder
of the both industrial and intellectual property rights identified herein. Recipient of this publication agrees to indemnify and hold harmless each entity of the LIPOTEC organization for any and all
regulatory action arising from recipients use of any claims or information in this publication, including, but not limited to, use in advertising and finished product label claims, and not present this
publication as evidence of finished product claim substantiation to any regulatory authority.
Isaac Peral 17 Pol. Industrial Cam Ral - 08850 Gav (Barcelona) Spain-Tel +34 93 638 80 00 / Fax +34 93 638 93 93 - [email protected]
Ed. 11A